Please assess the completion status of the following clinical trial:

Trial Title: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proof of colorectal cancer~* Initially unresectable metastases confined to the liver according to CT scan, obtained ≤3 weeks prior to registration. Unresectability should be confirmed by the liver expertpanel. Patients with small (≤ 1 cm) extrahepatic lesions that are not clearly suspicious of metastases are eligible~* Known mutation status of RAS and BRAF~* WHO performance status 0-1 (Karnofsky performance status ≥ 70)~* Age ≥ 18 years~* No contraindications for liver surgery~* In case of primary tumor in situ: tumor should be resectable~* In case of resected primary tumor: adequate recovery from surgery~* Adequate organ functions, as determined by normal bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft formula, ≥ 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases ≤ 5x ULN)~* Life expectancy \> 12 weeks~* Expected adequacy of follow-up~* Written informed consent~Exclusion Criteria:~* Extrahepatic metastases, with the exception of small (≤ 1 cm) extrahepatic lesions that are not clearly suspicious of metastases~* Unresectable primary tumor~* Serious comorbidity or any other condition preventing the safe administration of study treatment (including both systemic treatment and surgery)~* Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation~* Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3 antihypertensive drugs~* Previous systemic treatment for metastatic disease; previous adjuvant treatment is allowed if completed ≥ 6 months prior to randomisation~* Previous surgery for metastatic disease~* Previous intolerance of study drugs in the adjuvant setting~* Pregnant or lactating women~* Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin, or second primary colorectal cancer.~* Any concomitant experimental treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm B: FOLFOXIRI & bevacizumab (inclusion completed) (Type: EXPERIMENTAL): Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab
- Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed) (Type: ACTIVE_COMPARATOR): Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab
- Arm D: FOLFOX/FOLFIRI & panitumumab (Type: EXPERIMENTAL): Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab
- Arm C: FOLFOX/ FOLFIRI & bevacizumab (Type: ACTIVE_COMPARATOR): Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).